TLDR:
- Brighton-based biopharmaceutical company Enterprise Therapeutics has raised £26m in a series B follow-on funding round.
- The financing round was led by Panakes Partners and saw participation from existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group.
- The funds will be used to accelerate the Phase 2a clinical trial of Enterprise Therapeutics’ lead program, ETD001, to develop treatments for cystic fibrosis and expand clinical activities in Italy.
Brighton-based biopharmaceutical company Enterprise Therapeutics has secured £26m in series B follow-on funding. The round was led by Panakes Partners, with participation from existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group. The funds will be used to accelerate the Phase 2a clinical trial of Enterprise Therapeutics’ lead program, ETD001, which aims to develop treatments for cystic fibrosis. The clinical trial will test the effectiveness of ETD001 in improving lung function in patients with cystic fibrosis who are either ineligible for or not receiving CFTR modulators.
